Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2
inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims …

Aim To assess the efficacy and safety of combination therapy with a glucagon‐like peptide‐1
receptor agonist (GLP‐1 RA) and a sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) in …

Abstract GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) have been
associated with improved glycemic control, body weight loss and favorable changes in …

Purpose To evaluate the efficacy and safety of combination therapy with sodium–glucose
cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in …

Among persons with type 2 diabetes (t2d), the development of glucose intolerance involves
dysfunction in several organs and tissues, including the muscle, liver, pancreas, kidney …

Background This review evaluated the efficacy and safety of a combination therapy
comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl …

To assess the efficacy and safety of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors
plus a dipeptidyl peptidase‐4 (DPP‐4) inhibitor in patients with type 2 diabetes mellitus …

Context Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose
cotransporter-2 inhibitors (SGLT2is) are used off-label in the management of type 1 diabetes …

Aim To compare the efficacy and tolerability of sodium‐glucose co‐transporter 2 inhibitors
(SGLT‐2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in adults with type 2 …

Background Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …